$OLMA News

Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Olema Pharma Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate OP-3136 In Combination With NUBEQA In Patients With mCRPC

Olema Pharmaceuticals Reports Initial Clinical Data From The Phase 1 Study of OP-3136, A KAT6 Inhibitor, At 2026 ASCO Annual Meeting; OP-3136 Monotherapy Was Well-tolerated With No Dose-limiting Toxicities Observed And No Discontinuations Due To Treatment-related Adverse Events; OP-3136 Shows Evidence Of Anti-tumor Activity Across Multiple Solid Tumor Types

Olema: The Market Overreacted To Roche's SERD Failure

Guggenheim Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $35

Olema Pharmaceuticals (NASDAQ:OLMA) Reports Narrower Q1 Loss, Eyes Fall Breast Cancer Data Readout

Olema Pharmaceuticals Q1 EPS $(0.52) Beats $(0.53) Estimate

Olema Pharma To Present Phase 1 OP-3136 Data And Phase 3 OPERA-02 Trial Updates At ASCO 2026

Olema Pharmaceuticals Reveals Preclinical Data For Palazestrant and OP-3136 At The 2026 AACR Annual Meeting; Palazestrant's Mechanism Of Action Confirmed; Full Recruitment Of Corepressor Protein NCoR1 Enables Complete Antagonism Of The Estrogen Receptor; Palazestrant Is Currently Being Evaluated In Two Phase 3 Clinical Trials; OP-3136 Is Enrolling Patients In The Ongoing Phase 1 Study

Olema Pharmaceuticals Reveals Preclinical Data For Palazestrant and OP-3136 At The 2026 AACR Annual Meeting; Palazestrant's Mechanism Of Action Confirmed; Full Recruitment Of Corepressor Protein NCoR1 Enables Complete Antagonism Of The Estrogen Receptor; Palazestrant Is Currently Being Evaluated In Two Phase 3 Clinical Trials; OP-3136 Is Enrolling Patients In The Ongoing Phase 1 Study

Wolfe Research Initiates Coverage On Olema Pharmaceuticals with Peer Perform Rating

Jefferies Assumes Olema Pharmaceuticals at Buy, Lowers Price Target of $40

JP Morgan Maintains Overweight on Olema Pharmaceuticals, Raises Price Target to $58

Goldman Sachs Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $27

Citigroup Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $62

Guggenheim Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $38

Olema Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 ESP results.

Olema Pharmaceuticals Inc (NASDAQ:OLMA) Beats Q4 2025 EPS Estimates, Provides Key Pipeline Updates

Olema Pharmaceuticals Q4 EPS $(0.50) Beats $(0.53) Estimate

HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $38